SGEN's Adcetris news and updates from ASH have been released
Promising results, and they are getting quite a bit of positive notice on Twitter by biotech experts, but Yahoo has "improved" this message board to the point that it won't allow me to post the press release. You can find it on SGEN's website.
Let's see if it will work this way. Adcetris press release, part 1:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies from Multiple Presentations at ASH Annual Meeting
-34 Percent Objective Response Rate in Phase II Trial for Relapsed or Refractory Non-Hodgkin Lymphomas, Including 44 Percent in Diffuse Large B-cell Lymphoma (DLBCL)-
-Long-term Follow-up Demonstrates Durable Complete Remissions in Pivotal Systemic ALCL Trial-
-Investigator Data Describe CD30 Expression in up to 25 Percent of DLBCL Cases-
-Case Studies Indicate Activity of ADCETRIS in Systemic Mastocytosis-
ATLANTA--(BUSINESS WIRE)--Dec. 9, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today summarized ADCETRIS (brentuximab vedotin) and CD30 expression data in non-Hodgkin lymphomas and other malignancies from multiple presentations at the 54thAmerican Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Highlights include encouraging interim data from a phase II clinical trial of ADCETRIS in non-Hodgkin lymphoma and long-term follow up from a pivotal clinical trial of ADCETRIS in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). In addition, investigators presented data describing the expression of CD30 in DLBCL and case studies on ADCETRIS in patients with systemic mastocytosis. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
"This collection of data from both corporate studies as well as investigator research into CD30 and the clinical role of ADCETRIS in non-Hodgkin lymphomas add to a growing body of evidence that ADCETRIS has potential in a broad array of CD30-positive malignancies," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "The numerous data sets at ASH also reinforce our development strategy for the program and overall vision for ADCETRIS in the treatment of patients with significant unmet medical needs." CONTINUED